What Does the Evidence Show About Tysabri and PML?
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
Understanding Medication Risks in the Context of General Health
If you or a loved one is taking Tysabri and concerned about the risk of progressive multifocal leukoencephalopathy (PML), you need clear, evidence-based information. This page reviews what clinical studies can and cannot tell us about PML prognosis and treatment, building on decades of research into immunosuppression-related infections.
Tysabri and PML: A Clinical Overview
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, emphasizing that the drug increases PML risk and that healthcare professionals must monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Prognosis and Treatment for Severe PML After Tysabri
The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically relies on brain MRI and detection of JCV DNA in cerebrospinal fluid. The prognosis for PML after Tysabri is generally poor, with the boxed warning stating that the infection 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, outcomes can vary depending on factors such as early detection, immune status, and the extent of brain involvement. Treatment for severe PML after Tysabri primarily involves supportive care and efforts to restore immune function, such as plasma exchange or immunoadsorption to rapidly remove natalizumab from the circulation, thereby allowing immune reconstitution. There is no specific antiviral therapy approved for PML, though some investigational approaches have been explored. The goal of treatment is to halt viral replication and control the immune response, but neurological damage may be irreversible. Regarding the adequacy of warnings, the FDA has mandated a boxed warning that clearly states the PML risk and the need for monitoring. The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation; therefore, patients should continue to be monitored for at least six months after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For multiple sclerosis patients, an MRI scan should be obtained prior to initiating therapy to help differentiate subsequent MS symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease patients, a baseline brain MRI may also be helpful, though brain lesions at baseline that could cause diagnostic difficulty are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Risk Factors and Monitoring Recommendations
The timeline between Tysabri exposure and documented PML harm can vary. The risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur at any time during therapy, and cases have been reported after discontinuation, underscoring the need for continued vigilance. The boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom that may be suggestive of PML, and dosing should be withheld immediately at the first sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This proactive approach is critical because early detection and intervention may improve prognosis, though the infection often leads to severe disability or death. In summary, Tysabri-associated PML is a serious adverse event with a poor prognosis. The FDA has implemented strong warnings and a restricted distribution program to mitigate risk. Patients and healthcare providers must remain vigilant for early signs of PML, especially in those with identified risk factors, and act promptly to discontinue therapy if PML is suspected. Despite these measures, the potential for severe outcomes remains a significant concern in the risk-benefit assessment of Tysabri therapy.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the prognosis for PML after Tysabri treatment?
The prognosis for PML after Tysabri is generally poor, with the FDA boxed warning stating that the infection 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Outcomes can vary depending on early detection, immune status, and extent of brain involvement.
How is severe PML after Tysabri treated?
Treatment for severe PML after Tysabri primarily involves supportive care and efforts to restore immune function, such as plasma exchange or immunoadsorption to rapidly remove natalizumab from circulation. There is no specific antiviral therapy approved for PML, though investigational approaches exist. The goal is to halt viral replication and control immune response, but neurological damage may be irreversible.
What are the risk factors for developing PML while on Tysabri?
Three primary risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.